Background: The reduced glomerular filtration rate in the advanced stages of chronic kidney
Introduction
Chronic kidney disease (CKD) is characterized by progressive loss of renal function, with the final stage being end-stage renal disease (ESRD) 1 . At this stage, patients require permanent renal replacement therapy, i.e. hemodialysis (HD)/peritoneal dialysis (PD) or transplantation 1 . As kidney function declines, there is a progressive increase in both mortality and co-morbidities, such as cardiovascular complications [2] [3] [4] [5] [6] .
The molecular mechanisms involved in CKD and ESRD complications are complex and comprise coagulation abnormalities, endothelial dysfunction, vascular calcification due to impaired calcium and phosphate metabolism, increased oxidative and metabolic stress and inflammation [7] [8] [9] [10] . The reduced glomerular filtration rate (GFR) in the advanced stages of CKD affects blood clearance and leads to subsequent accumulation of organic products (uremic retention solutes) and drugs that are normally metabolized or excreted by the kidney. Such uremic retention solutes include proteins, and may induce toxic effects 11, 12 . Significant changes in the blood protein composition have been reported in the past [13] [14] [15] [16] [17] , and it has been hypothesized that these changes in plasma proteins may, at least in part, be responsible for CKD-associated morbidity and mortality 13, 14, 18 . However these different studies mostly focused on the role of individual proteins and this promising yet disparate molecular evidence indicates a clear need for a holistic, large-scale approach. Plasma proteomics (i.e. analysis of the total plasma protein content) could be of particular interest to provide an integrated view and better understanding of CKD-associated complications. The recent advancement in proteomics technologies and software solutions have enabled assessing highly complex samples with high validity 19, 20 ,
indicating that high-resolution plasma proteome analysis should inform about CKD-associated molecular changes.
The rationale of the present study was to apply untargeted high-resolution plasma proteome analysis to investigate molecular changes associated with CKD. Our aim was to identify proteins with altered plasma levels and estimate the functional consequences of such changes.
Material and Methods

Patients
The discovery cohort consisted of 29 patients with CKD. Fourteen CKD patients not The validation cohort consisted out of 32 CKD patients and 8 healthy controls selected from the sample collection of the Nephrology Department of the Ghent University Hospital, Belgium. Subjects were sampled under fasting conditions between January 2011 and July 2012.
The study was approved by the local ethical committee (Belgian registration number B67020107926). The study was in accordance with the principles of the Declaration of Helsinki.
Written informed consent was obtained from all participants before sampling.
Patients on hemodialysis underwent either hemodialysis or online-hemodiafiltration 3 times 4 hours a week. The quality of the dialysis fluid met the ultrapure standards (bacteria <0.1 CFU/ml, endotoxin <0.03 EU/ml) as checked on a regular basis. Plasma samples were collected prior to dialysis, before anticoagulant administration. One patient on home hemodialysis was sampled when consulting the out-patient clinic.
K-EDTA-plasma samples were processed immediately after collection and stored at -80°C. Urine protein, C-reactive protein and creatinine concentrations were determined by routine techniques by the hospital laboratory. eGFR was calculated based on serum creatinine using the CKD-EPI creatinine equation. Proteinuria was determined using urine dipstick or with >0.25g
protein/g creatinine.
Sample preparation for proteomic analysis
Ten μL of thawed plasma sample was diluted with 90 μL 0.1% sodium dodecyl sulfate, 20mM
dithiothreitol, and 0.1 M TrisHCl (pH=7.6). The sample was sonicated at room temperature for 30 minutes, followed by denaturation at 95°C for 3 min. Samples were subsequently incubated with 50 mM Iodoacetamide at room temperature for 30 min in the dark followed by the addition of ammonium bicarbonate buffer solution (300 μL, 50mM), applied to NAP-5 column, and eluted with 1 mL of 50mM ammonium bicarbonate buffer solution.
Twenty μg of lyophilized trypsin was added to 50 μL of activation buffer solution, and 2 μL of this solution was added to the eluted sample. Trypsin digestion was carried out overnight at a temperature of 37°C. Samples were then lyophilized, stored at 4°C and resuspended in 100 μL HPLC-grade H 2 O shortly before mass spectrometry analysis.
Proteome analysis
The plasma extracts (5 μl) were analysed by nanoflow LC-MS/MS using a Orbitrap velos FTMS as per 19 . The gradient was run from at 1% B for 5 mins rising to 25% B after 360 mins then on to 65% B after 480 mins.
Proteomics data processing
Peptide analysis was performed using SEQUEST against the Human Uniprot Database as per 19 .
The relative quantitative analysis was performed based on the peptide area values. Before analysis, ppm-normalization of peptide areas was conducted.
Normalized mass-peak area = Peptide mass-peak area / Total sample mass-peak area x 10 
Results
Plasma proteome analysis
We studied the plasma proteome of 14 patients with moderate CKD (stage 2 and 3, CKD2-3 group) and 15 patients on hemodialysis for at least one year (CKD5/HD group) ( Table   1) . A schematic of the design is given in Figure 1 . LC-MS/MS analysis enabled identification of 9017 peptides (Supplementary Table 1 ), representing a total of 2054 unique proteins quantified using a label-free approach (Supplementary Table 2 ). To assess the validity of the quantification strategy, the reported concentration of 20 high abundant plasma proteins [21] [22] [23] (Supplementary   Table 3 ) was compared to their respective relative abundance in the LC-MS/MS experiment (normalized-ppm mass-peak area, arbitrary units). As evident from Figure (Table 1 ) and semi-quantitative LC-MS/MS abundance in the discovery cohort ( Figure 2B ), confirming the validity of the approach.
Plasma proteome changes in CKD5/HD versus CKD2-3 patients
When comparing the 15 datasets from patients on HD with the 14 from patients at early stage CKD, we identified 333 proteins as significantly different between the two groups, 127
with lower and 206 with higher abundance in CKD5/HD compared to CKD2-3 (Supplementary Table 2 ). Upon correction for multiple testing, 39 of the 333 remained significant (Table 2 ). To exclude bias introduced by age or gender, we also investigated an age-and sex-matched subcohort of 7 CKD2-3 patients and 7 CKD5/HD patients (Table 1) . Although this subcohort comparison is of lower statistical power, the initial results could be generally confirmed (Table   2 ).
Using LC-MS/MS, we confirmed increased abundance of 7 of 39 well-characterized uremic toxins 11, 12 including beta-2-microglobulin and prostaglandin-H2 D-isomerase, while two of them were detected but showed unmodified abundance (i.e. immunoglobulins kappa and lambda) (Supplementary Table 4 ).
Pathway analysis
Functional analysis of the 333 modified plasma proteins was performed using Gene Ontology (GO) and Ingenuity Pathway Analysis (IPA) software. The pathways with the highest modification scores included acute phase response signaling and complement and coagulation systems ( Figure 3 -4, Supplementary Table 5 ). Other pathways included platelet degranulation, calcium ion-dependent exocytosis, response to selenium ion, liver X receptor (LXR)/retinoid R receptor (RXR) activation, atherosclerosis signaling and production of nitric oxide (NO) and reactive oxygen species (ROS) (Supplementary Table 5 ).
Of the 33 proteins associated with the complement system, 24 were detected in the plasma using LC-MS/MS. Among those 5 were significantly increased in abundance in the plasma of patients at CKD5/HD compared to CKD2-3 ( Figure 3A ), suggesting activation of the complement system in advanced CKD. On the other hand, 23 out of 35 proteins associated with the coagulation system were detected in the plasma using LC-MS/MS (not shown), and levels of 5 were significantly modified, 3 with lower, and 2 with higher abundance in CKD5/HD compared to CKD2-3 ( Figure 3B ). From a total of 169 proteins associated with acute phase response signaling in Ingenuity database, 62 were detected in plasma and 17 were significantly modified in CKD5/HD patients ( Figure 4 ). Most of these changes were in accordance with the activation of the pathway ( Figure 4 ): 9 proteins known to be increased in the plasma during the acute phase response were found to be more abundant, and 4 known to be decreased were found to be less abundant in CKD5/HD compared to CKD2-3 ( Figure 4 ). In particular, CRP levels determined by LC-MS/MS or routine analysis showed similar increase in the plasma of CKD5/HD patients compared to CKD2-3 ( Figure 4 , Bold and Table 1 ), confirming activation of the acute phase response in CKD. Of note, the same analysis was performed after exclusion of 6 patients of the CKD5/HD group with highest CRP values and this lead to same results.
Validation of newly identified plasma proteins using ELISA
We next aimed to validate key novel proteins in an independent cohort of healthy controls and patients with stage 3b (CKD3b), stage 4 (CKD4), and stage 5 CKD not on HD (CKD5 no HD) and on HD (CKD5/HD)(n=8/group), all matched for age and gender (Table 1) using ELISA. We confirmed that the abundance of complement factor D, lysozyme C and leucine-rich alpha-2 glycoprotein were significantly increased in plasma of CKD5 patients compared to controls. We further showed that their abundance progressively increased during CKD progression ( Figure 5A-5C ). We also demonstrated that protein levels were increased in the We next assessed the association of complement factor D, lysozyme C, leucine-rich alpha-2 glycoprotein and histidine-rich glycoprotein to the occurrence of all-cause mortality in CKD patients after a follow-up period of 3.14±0.14 years post sampling ( Figure 6 ). In the discovery cohort, no mortality was observed in the CKD2-3 patient group. From the 15 patients of the CKD5/HD group, two patients were excluded as one was transplanted and one was lost for follow-up. Among the 13 remaining patients, 10 died and 3 were still alive at the last follow-up.
We determined the median LC-MS/MS abundance as the threshold for the four proteins. We observed that high abundance of leucine-rich alpha-2 glycoprotein was significantly associated with higher mortality in patients with CKD5 on hemodialysis compared to patients with low leucine-rich alpha-2 glycoprotein abundance ( Figure 6C 
Discussion
The aim of the present study was to assess global plasma protein changes in late stage Table 4 ).
To verify our findings, we focused on new candidates generally not described in the context of CKD (lysozyme C, leucine-rich alpha-2-glycoprotein and histidine-rich glycoprotein).
Using ELISA, we observed in an independent validation cohort that lysozyme C and leucine-rich alpha-2-glycoprotein abundance was increased in CKD patients compared to healthy controls, and were further increased during HD ( Figure 5 ). Conversely, although histidine-rich glycoprotein level was clearly significantly decreased in ESRD as measured using LC-MS/MS, we were not able to confirm this difference using ELISA. Such technical discrepancy between MS-based and antibody-based approaches such as western blot or ELISA is not uncommon and has been observed in other proteome studies [24] [25] [26] , making the validation process, yet necessary, sometimes difficult.
Circulating lysozyme C, a protein released from leukocytes and macrophages and primarily known for its bacteriolytic function, binds to the endocardial endothelium and within the vascular smooth muscle layer of arteries, leading to the generation of hydrogen peroxide and nitric oxide and ultimately causing persistent systemic vasodilatation and myocardial depression 27, 28 . Leucine-rich alpha-2-glycoprotein is a secreted glycoprotein of not too well known function and has been linked to different type of cancer, appendicitis and ulcerative colitis [29] [30] [31] [32] [33] [34] . It also promotes aberrant angiogenesis 35 which is a key feature of a number of diseases including age-related macular degeneration, diabetic retinopathy, cancer, atherosclerosis and plaque rupture 36 . Moreover, leucine rich alpha-2 glycoprotein was previously shown to be excreted in the urine of patients with IgA nephropathy and CKD 37, 38 . Plasma accumulation of the proteins was significantly correlated with renal function decline (Supplementary Figure) , showing that the increased plasma levels of the molecules reflect at least in part alteration of glomerular filtration.
Although we do not know whether this accumulation can be responsible for the development of complications in patients with advanced CKD, it is interesting to note that increased plasma level of lysozyme C was significantly associated with atheromatous disease and could predict the severity of coronary artery disease 39 , while increased serum leucine-rich alpha-2-glycoprotein has been found to be a biomarker of heart failure 29 .
The functional relevance of the 333 proteins identified with our proteomic approach and their putative prognostic value, are to be further explored. As a first attempt to gain inside we assessed the cellular activities to which these proteins are related with and observed that many of them participate in acute phase response and complement and coagulation system activation In light of our results, further studies should be performed in order to better understand the origin and the role complement factor D and complement system in patients with CKD and HD and its link to vascular disease.
In addition to these inflammatory risk factors, changes in the expression of coagulation factors F5, F10 and F12, as well as in plasma kallikrein (Klkb1), proteins related to blood coagulation and platelet activation ( Figure 3B and Supplementary Table 5 ) were observed.
Changes in hemostasis are well described in CKD 41 due to uremic toxins, interaction with dialyzer membranes and the repeated use of anticoagulants all together contributing to the risk of cardiovascular and thrombotic complications in patients undergoing HD 41 . In 1996, Tan et al analyzed the plasma activity of different coagulation factors in patients with IgA nephropathy and found that IgA patients had significantly lower plasma activity of F12 and Klkb1 compared to healthy controls, which was consistent with our observations 45 . More recently, the plasma activity of F5 was found significantly higher in diabetic patients with renal disease compared with diabetic patients without renal disease 46 , a finding in accordance with the observed increased level of F5 in the plasma of CKD patients. However, in this study, plasma activity of F10 tended to decrease as observed in our study but this not reached significant level 46 .
One of the main limitations of this study is that observed molecular changes have not been related to clinical endpoints such as infections, hemorrhages, atherosclerosis or cardiovascular events except for leucine-rich alpha-2 glycoprotein for which we observed that high plasma levels are significantly associated with higher mortality in patients with CKD5 on hemodialysis compared to patients with low leucine-rich alpha-2 glycoprotein abundance ( Figure   6C ). Indeed, this study was designed as a discovery study to first identify new candidate proteins among a broad array of hundreds of potential candidates with significant plasma changes, which may in subsequent studies enable better understanding of HD-associated complications.
In conclusion, in this study we have generated for the first time a comprehensive assessment of the plasma proteome of ESRD patients in comparison to early stage CKD, in a cohort of significant size that enabled identification of a large array of proteins altered in ESRD, using high-resolution LC-MS/MS analysis. This study serves as a basis for future studies investigating the relevance of the observed changes, but also as a well-defined comparator for similar studies in the future. In addition, the data may serve for further biomarker identification and systems biology-based assessment of the molecular mechanisms involved CKD-associated morbidity and mortality.
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